| Ytd | -3.79% | |
| 1y | -7.97% |
| Open | 1.29 | Prev Close | 1.28 | Low | 1.26 | High | 1.31 | Mkt Cap | 814.73M |
| Vol | 9.91M | Avg Vol | 15.67M | EPS | -0.11 | P/E | N/A | Forward P/E | 19.50 |
| Beta | 0.67 | Short Ratio | 4.30 | Inst. Own | 77.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 1.33 | 200-d Avg | 1.39 | 1yr Est | 3.40 |
Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutiv
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and effica
Geron (NASDAQ:GERN) reported quarterly losses of $(0.01) per share which beat the analyst consensus
U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear
Geron (NASDAQ:GERN) reported quarterly losses of $(0.05) per share which missed the analyst consensu
On December 16, 2025, Geron Corporation (the "Company") began implementation of a strategic
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cyt
2025 Financial GuidanceFor fiscal year 2025, the Company expects total operating expenses will be be
New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores rela
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial
Geron (NASDAQ:GERN) reported quarterly losses of $(0.02) per share which beat the analyst consensus
Goldman Sachs analyst Corinne Jenkins reinstates Geron (NASDAQ:GERN) with a Sell and announces $1
Goldman Sachs analyst Corinne Jenkins initiates coverage on Geron (NASDAQ:GERN) with a Sell ratin
New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with l
Geron (NASDAQ:GERN) reported quarterly losses of $(0.03) per share which beat the analyst consensus
Scotiabank analyst Greg Harrison maintains Geron (NASDAQ:GERN) with a Sector Outperform and lower
Stifel analyst Stephen Willey maintains Geron (NASDAQ:GERN) with a Buy and lowers the price targe
Barclays analyst Peter Lawson maintains Geron (NASDAQ:GERN) with a Overweight and lowers the pric
Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target fro
Geron (NASDAQ:GERN) reported quarterly losses of $(0.04) per share which beat the analyst consensus
B. Riley Securities analyst Kalpit Patel maintains Geron (NASDAQ:GERN) with a Buy and lowers the
Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and raises the price target fro
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
In the dose escalation Part 1 of the study, no dose-limiting toxicities were observed and the PK pro
HC Wainwright & Co. analyst Emily Bodnar reiterates Geron (NASDAQ:GERN) with a Buy and mainta
Geron received $250 million in gross proceeds at closing, with access to an additional $125 million
Geron (NASDAQ:GERN) reported quarterly losses of $(0.04) per share which beat the analyst consensus
HC Wainwright & Co. analyst Emily Bodnar reiterates Geron (NASDAQ:GERN) with a Buy and mainta